Browse studies

Find your next paid study

5 recruiting studies matching your filters

A Phase I Study of Metronomic Temozolomide With Abexinostat (PCI-24781) for Patients With Recurrent High Grade Glioma

Glioblastoma (GBM), WHO grade IV glioma, represents the majority of adult malignant primary brain tumors, with an incidence of 2-3 per 100,000 person-years. Th…

Recurrent High Grade GliomaAnaplastic AstrocytomaAnaplastic Oligodendroglioma+2 more

Estimated

~$10 – $6,250

University of NebraskaNCT05698524

Phase 2

Phase II Trial of Treatment Intensification for IDH Wildtype, Non-Histological Glioblastoma, Gliomas (IDH Wildtype Lower Grade Glioma Treatment Intensification)

This phase II trial studies how well temozolomide and radiation therapy work in treating patients with IDH wildtype historically lower grade gliomas or non-his…

Anaplastic Astrocytoma, IDH-WildtypeAnaplastic OligoastrocytomaAnaplastic Oligodendroglioma+6 more

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT04623931

Phase 1

Phase I/IIa Trial of Retifanlimab and Difluoromethylornithine (DFMO) in Patients With Progressive High-Grade Glioma

This phase I/II trial tests the safety, side effects best dose and effect of retifanlimab with or without difluoromethylornithine (DFMO) for the treatment of h…

Anaplastic OligodendrogliomaAstrocytoma, IDH-Mutant, Grade 3Astrocytoma, IDH-Mutant, Grade 4+3 more

Estimated

~$10 – $6,250

Mayo ClinicNCT07468136

Phase 1

A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the max…

Central Nervous System NeoplasmsGlioblastomaGliosarcoma, Adult+20 more

A Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Primary Brain Tumors

This pilot study will assess the safety and feasibility of using an implantable microdevice to measure local intratumor response to chemotherapy and other clin…

Grade II GliomaGrade III GliomaGrade IV Glioma+5 more

Estimated

~$10 – $7,500

Oliver JonasNCT04135807